中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
EVALUATION AND ANAL YSIS OF DRUG-USE IN HOSPITALS OF CHINA
2015年
6期
765-768,769
,共5页
刘秀书%曹艳%杜岚%邹爱英%尹世强
劉秀書%曹豔%杜嵐%鄒愛英%尹世彊
류수서%조염%두람%추애영%윤세강
肺疾病,慢性阻塞性%Meta分析%随机对照试验%福莫特罗%系统评价
肺疾病,慢性阻塞性%Meta分析%隨機對照試驗%福莫特囉%繫統評價
폐질병,만성조새성%Meta분석%수궤대조시험%복막특라%계통평개
Pulmonary disease,Chronic obstructive%Meta-analysis%Randomized controlled trial%Formoterol%Systematic evaluation
目的:评价福莫特罗与茚达特罗治疗慢性阻塞性肺疾病( COPD)的疗效和安全性。方法:检索中英文数据库,福莫特罗对比安慰剂或茚达特罗治疗COPD的随机对照试验( RCT)和系统评价( SR),对纳入的RCT进行方法学质量评价和meta分析。结果:与安慰剂比较,福莫特罗可显著改善COPD患者生活质量,差异具有统计学意义( P<0.01);与福莫特罗比较,茚达特罗可显著改善COPD患者用力1秒呼气量,差异具有统计学意义( P<0.01);福莫特罗与安慰剂或茚达特罗其余指标比较差异均无统计学意义(P>0.05)。结论:福莫特罗和茚达特罗均可改善COPD患者生活质量,且茚达特罗还可显著改善患者肺功能,因此,茚达特罗是值得在临床推广的COPD治疗方法。
目的:評價福莫特囉與茚達特囉治療慢性阻塞性肺疾病( COPD)的療效和安全性。方法:檢索中英文數據庫,福莫特囉對比安慰劑或茚達特囉治療COPD的隨機對照試驗( RCT)和繫統評價( SR),對納入的RCT進行方法學質量評價和meta分析。結果:與安慰劑比較,福莫特囉可顯著改善COPD患者生活質量,差異具有統計學意義( P<0.01);與福莫特囉比較,茚達特囉可顯著改善COPD患者用力1秒呼氣量,差異具有統計學意義( P<0.01);福莫特囉與安慰劑或茚達特囉其餘指標比較差異均無統計學意義(P>0.05)。結論:福莫特囉和茚達特囉均可改善COPD患者生活質量,且茚達特囉還可顯著改善患者肺功能,因此,茚達特囉是值得在臨床推廣的COPD治療方法。
목적:평개복막특라여인체특라치료만성조새성폐질병( COPD)적료효화안전성。방법:검색중영문수거고,복막특라대비안위제혹인체특라치료COPD적수궤대조시험( RCT)화계통평개( SR),대납입적RCT진행방법학질량평개화meta분석。결과:여안위제비교,복막특라가현저개선COPD환자생활질량,차이구유통계학의의( P<0.01);여복막특라비교,인체특라가현저개선COPD환자용력1초호기량,차이구유통계학의의( P<0.01);복막특라여안위제혹인체특라기여지표비교차이균무통계학의의(P>0.05)。결론:복막특라화인체특라균가개선COPD환자생활질량,차인체특라환가현저개선환자폐공능,인차,인체특라시치득재림상추엄적COPD치료방법。
OBJECTIVE:To evaluate the efficacy and safety of fomoterol and indatero in the treatment of chronic obstructive pulmonary disease ( COPD) .METHODS: The databases either in English or Chinese were searched for randomized controlled trials ( RCTs) or systematic review of formoterol as compared with placebo or indacaterol for treatment of COPD.The included RCTs were subjected to evaluation of the methodological quality and meta-analysis. RESULTS:Compared with placebo, formoterol significantly improved the quality of life of patients with COPD, and the difference was statistically significant (P<0.01);compared with formoterol, indinavir significantly improved FEV1 in patients with COPD, and the difference was statistically significant ( P<0.01 ) .There were no significant differences between formoterol and placebo or indinavir in other indices ( P >0.05 ) .CONCLUSIONS: Both formoterol and indacaterol can improve the quality of life of patients with COPD, and indacaterol also can significantly improve lung function in patients with COPD, indatero, therefore, is worthy of wide clinical application in the treatment of COPD.